Fidaxomicin
Fidaxomicin is a macrolide antibiotic used primarily for the treatment of Clostridioides difficile infection (CDI), a condition that can cause severe diarrhea and colitis. It is known for its narrow spectrum of activity, which targets Clostridioides difficile with minimal impact on the normal gut flora.
Mechanism of Action[edit | edit source]
Fidaxomicin works by inhibiting the bacterial enzyme RNA polymerase, which is essential for transcription and subsequent protein synthesis. This inhibition leads to the death of the bacteria, effectively treating the infection.
Pharmacokinetics[edit | edit source]
Fidaxomicin is minimally absorbed from the gastrointestinal tract, which allows it to act locally in the intestines. This property is beneficial as it reduces the risk of systemic side effects and maintains a high concentration of the drug at the site of infection.
Clinical Use[edit | edit source]
Fidaxomicin is specifically indicated for the treatment of Clostridioides difficile infection in adults. It is often reserved for cases where other treatments, such as metronidazole or vancomycin, have failed or are not suitable.
Side Effects[edit | edit source]
Common side effects of fidaxomicin include nausea, vomiting, and abdominal pain. Serious side effects are rare but can include hypersensitivity reactions.
Comparison with Other Treatments[edit | edit source]
Compared to other antibiotics like metronidazole and vancomycin, fidaxomicin has a lower recurrence rate of Clostridioides difficile infection. This makes it a valuable option in the management of recurrent CDI.
History[edit | edit source]
Fidaxomicin was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of Clostridioides difficile infection. It was developed by Optimer Pharmaceuticals and is marketed under the brand name Dificid.
Research and Development[edit | edit source]
Ongoing research is exploring the use of fidaxomicin in pediatric populations and its potential effectiveness against other bacterial infections.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
